Mumbai's benchmarks closed lower for a sixth consecutive session on Friday, 26 September, with the Sensex shedding 733.22 points, or about 0.9%, to settle at 80,426.46 and the Nifty 50 down 236.15 points at 24,654.70. Every sectoral index on the NSE finished in the red, but the damage was concentrated in the two export engines that have carried the market through most of 2026: pharmaceuticals and information technology.
The final leg of selling followed a fresh Washington headline on US tariffs covering branded drugs and trucks. Pharma had spent most of September as the defensive corner of the market, and that status did not survive the session. The tariff overhang lands directly on companies whose US generic and specialty revenue is earned in dollars, and closing-bell reports put the sector at the front of the decline.
Who led the fall
Pharma led on the way down, not on fundamentals reported this week but on policy risk imported from the US market. That matters for the tape because the sector had been where domestic funds parked money when the news cycle turned hostile. When the defensive pocket sells off, there is no natural place for the next rupee of allocation to hide, and index-level losses get steeper than the underlying earnings news would justify.
IT fell alongside, with the export-basket read-through and a cautious global risk tone keeping buyers away rather than any company-specific development. The two sectors together carry a heavy weight in the Nifty and command premium valuations, so a joint drawdown translates quickly into headline index losses.
The rupee is doing part of the damage
The currency has been the quieter pressure point. The rupee was quoted around 95.88 against the dollar, with traders describing pre-open dollar sales by the central bank as a steadying hand rather than a change of direction. For a market already selling exporters, a currency pinned near its weaker levels cuts both ways: it lifts the rupee value of dollar revenue, but it also raises the cost of imported inputs and keeps foreign investors cautious about unhedged exposure.
That is why the tariff headline did more work than its direct earnings impact would suggest. It arrived on a tape where the currency is fragile, foreign flows are hesitant, and the domestic institutional bid that cushioned earlier drawdowns this month has already had to absorb six sessions of supply.
Capex and reserves are the counterweight
Against that, the domestic macro numbers still argue for patience. The RBI's September bulletin flagged an economy that is resilient but exposed to downside risks from the West Asia conflict, with a pickup in August consumer inflation and a strong first quarter. Foreign exchange reserves stood at $766 billion as of 18 September, covering about 11.2 months of imports.
The central bank's own work on the investment cycle points the same way. Private corporate capex is estimated at ₹3.2 lakh crore for 2026-27, up from ₹2.6 lakh crore in 2025-26, funded through banks, financial institutions, external commercial borrowings and IPOs. A pipeline that size is a slow-moving support for earnings, not a same-day support for prices — which is precisely the gap the market is trading right now.
What would unwind it by Friday
Three things would break the streak in Mumbai hours. A clarification from Washington that narrows the tariff scope, or signals a negotiating track, would take the pharma overhang off the table fastest. A softer crude print, given the bulletin's explicit West Asia caveat, would ease both the import bill and the inflation arithmetic. And a rupee that holds below 96 to the dollar would remove the currency anxiety that has been amplifying every export-sector headline.
The domestic trigger sits just outside this week: the monetary policy committee meets 5-7 October, with August inflation already showing a pickup. Until then, the question for traders is narrower than the macro debate. Does pharma stop falling on its own, or does the market need the tariff story to be formally walked back first? Six sessions in, the answer is still no — and that is the level at which the Nifty enters the weekend.